Schaufelberger S, Schaettin M, Azzarito G, Rosselli M, Leeners B, Dubey R
Cells. 2024; 13(13.
PMID: 38994940
PMC: 11240791.
DOI: 10.3390/cells13131086.
Gopinath P, Oviya R, Gopisetty G
Mol Biol Rep. 2023; 50(11):9497-9509.
PMID: 37731028
DOI: 10.1007/s11033-023-08793-8.
Alhakamy N, Ahmed O, Fahmy U, Md S
Polymers (Basel). 2021; 13(6).
PMID: 33805675
PMC: 7998642.
DOI: 10.3390/polym13060884.
Jackson E, Gillespie D, Tofovic S
J Pharmacol Exp Ther. 2020; 373(1):135-148.
PMID: 32015161
PMC: 7174788.
DOI: 10.1124/jpet.119.263467.
Caira M, Bourne S, Samsodien H, Smith V
Beilstein J Org Chem. 2016; 11:2616-30.
PMID: 26734107
PMC: 4685897.
DOI: 10.3762/bjoc.11.281.
2-Methoxyestradiol, an endogenous 17β-estradiol metabolite, inhibits microglial proliferation and activation via an estrogen receptor-independent mechanism.
Schaufelberger S, Rosselli M, Barchiesi F, Gillespie D, Jackson E, Dubey R
Am J Physiol Endocrinol Metab. 2016; 310(5):E313-22.
PMID: 26732685
PMC: 4773653.
DOI: 10.1152/ajpendo.00418.2015.
2-Methoxyestradiol blocks the RhoA/ROCK1 pathway in human aortic smooth muscle cells.
Rigassi L, Barchiesi Bozzolo F, Lucchinetti E, Zaugg M, Fingerle J, Rosselli M
Am J Physiol Endocrinol Metab. 2015; 309(12):E995-1007.
PMID: 26487003
PMC: 4816197.
DOI: 10.1152/ajpendo.00267.2015.
2-methoxyestradiol and disorders of female reproductive tissues.
Pinto M, Medina R, Owen G
Horm Cancer. 2014; 5(5):274-83.
PMID: 24764201
PMC: 10358170.
DOI: 10.1007/s12672-014-0181-2.
Catechol--methyltransferase: characteristics, polymorphisms and role in breast cancer.
Yager J
Drug Discov Today Dis Mech. 2013; 9(1-2):e41-e46.
PMID: 23734165
PMC: 3665426.
DOI: 10.1016/j.ddmec.2012.10.002.
Epistasis analysis for estrogen metabolic and signaling pathway genes on young ischemic stroke patients.
Hsieh Y, Jeng J, Lin H, Hu C, Yu C, Lien L
PLoS One. 2012; 7(10):e47773.
PMID: 23112845
PMC: 3480403.
DOI: 10.1371/journal.pone.0047773.
A low COMT activity haplotype is associated with recurrent preeclampsia in a Norwegian population cohort (HUNT2).
Roten L, Fenstad M, Forsmo S, Johnson M, Moses E, Austgulen R
Mol Hum Reprod. 2011; 17(7):439-46.
PMID: 21355050
PMC: 3116680.
DOI: 10.1093/molehr/gar014.
Candidate genes and mechanisms for 2-methoxyestradiol-mediated vasoprotection.
Barchiesi F, Lucchinetti E, Zaugg M, Ogunshola O, Wright M, Meyer M
Hypertension. 2010; 56(5):964-72.
PMID: 20921434
PMC: 3023414.
DOI: 10.1161/HYPERTENSIONAHA.110.152298.
Therapeutic promises of 2-methoxyestradiol and its drug disposition challenges.
Verenich S, Gerk P
Mol Pharm. 2010; 7(6):2030-9.
PMID: 20831190
PMC: 3059899.
DOI: 10.1021/mp100190f.
Potential vascular actions of 2-methoxyestradiol.
Dubey R, Jackson E
Trends Endocrinol Metab. 2009; 20(8):374-9.
PMID: 19734053
PMC: 2761235.
DOI: 10.1016/j.tem.2009.04.007.
